217 related articles for article (PubMed ID: 29084060)
1. Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods.
Lloyd IE; Zhou W; Witt BL; Chadwick BE
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):107-113. PubMed ID: 29084060
[TBL] [Abstract][Full Text] [Related]
2. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
[TBL] [Abstract][Full Text] [Related]
3. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
5. Validation of 31 of the most commonly used immunohistochemical antibodies in cytology prepared using the Cellient(®) automated cell block system.
Montgomery E; Gao C; de Luca J; Bower J; Attwood K; Ylagan L
Diagn Cytopathol; 2014 Dec; 42(12):1024-33. PubMed ID: 24678031
[TBL] [Abstract][Full Text] [Related]
6. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
7. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
Jain D; Sukumar S; Mohan A; Iyer VK
Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
[TBL] [Abstract][Full Text] [Related]
9. Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
Anticancer Res; 2019 May; 39(5):2561-2567. PubMed ID: 31092453
[TBL] [Abstract][Full Text] [Related]
10. Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones.
Forest F; Cote G; Laville D; Da Cruz V; Dal Col P; Camy F; Mobarki M; Clemenson A; Yvorel V; Péoc'h M
Virchows Arch; 2019 Dec; 475(6):693-699. PubMed ID: 31267202
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
12. Effective application of the methanol-based PreservCyt(™) fixative and the Cellient(™) automated cell block processor to diagnostic cytopathology, immunocytochemistry, and molecular biology.
van Hemel BM; Suurmeijer AJ
Diagn Cytopathol; 2013 Aug; 41(8):734-41. PubMed ID: 23444168
[TBL] [Abstract][Full Text] [Related]
13. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
[TBL] [Abstract][Full Text] [Related]
14. Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.
Skov BG; Skov T
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):453-459. PubMed ID: 28549039
[TBL] [Abstract][Full Text] [Related]
15. CytoLyt fixation impedes insulinoma-associated protein 1 (INSM1) immunoreactivity compared to formalin fixation.
Garlin-Politis M; Upadhyay Baskota S; Picon S; Collins N; Virk RK; Cimic A; Yousefi E; Gonzalez A
J Am Soc Cytopathol; 2024; 13(3):213-218. PubMed ID: 38575468
[TBL] [Abstract][Full Text] [Related]
16. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
18. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
19. Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.
Phillips T; Millett MM; Zhang X; Jansson M; Cleveland R; Simmons P; Cherryholmes G; Carnahan J; William J; Spaulding B; Satnick IR; Inzunza HD; Taylor C; Cogswell J; Novotny J; Oroudjev E; Winther H
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):6-12. PubMed ID: 29189265
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
